Clovis Oncology (NASDAQ:CLVS) is set to announce its earnings results after the market closes on Tuesday, February 20th. Analysts expect the company to announce earnings of ($1.29) per share for the quarter.
Shares of Clovis Oncology (NASDAQ CLVS) opened at $53.06 on Tuesday. The company has a market cap of $2,600.00, a P/E ratio of -6.41 and a beta of 1.05. The company has a quick ratio of 3.16, a current ratio of 3.19 and a debt-to-equity ratio of 0.94. Clovis Oncology has a 12 month low of $45.42 and a 12 month high of $99.45.
In other news, Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $64.97, for a total transaction of $292,365.00. Following the completion of the sale, the director now directly owns 21,118 shares of the company’s stock, valued at approximately $1,372,036.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $63.70, for a total transaction of $191,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 18,000 shares of company stock valued at $1,123,425 over the last three months. Corporate insiders own 12.50% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Clovis Oncology (CLVS) Scheduled to Post Quarterly Earnings on Tuesday” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/13/clovis-oncology-clvs-scheduled-to-post-quarterly-earnings-on-tuesday.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.